Jinhe Biotechnology Valuation
| 002688 Stock | 4.33 0.03 0.69% |
At this time, the firm appears to be overvalued. Jinhe Biotechnology retains a regular Real Value of USD3.68 per share. The prevalent price of the firm is USD4.33. Our model calculates the value of Jinhe Biotechnology from evaluating the firm fundamentals such as Return On Asset of 0.0223, return on equity of 0.0371, and Current Valuation of 4.94 B as well as inspecting its technical indicators and probability of bankruptcy.
Price Book 1.4908 | Enterprise Value 4.9 B | Enterprise Value Ebitda 43.9826 | Price Sales 1.4707 | Trailing PE 35.9167 |
Overvalued
Today
Please note that Jinhe Biotechnology's price fluctuation is moderately volatile at this time. Calculation of the real value of Jinhe Biotechnology is based on 3 months time horizon. Increasing Jinhe Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Jinhe Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Jinhe Stock. However, Jinhe Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.33 | Real 3.68 | Hype 4.33 | Naive 4.82 |
The real value of Jinhe Stock, also known as its intrinsic value, is the underlying worth of Jinhe Biotechnology Company, which is reflected in its stock price. It is based on Jinhe Biotechnology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Jinhe Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Jinhe Biotechnology Co helps investors to forecast how Jinhe stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Jinhe Biotechnology more accurately as focusing exclusively on Jinhe Biotechnology's fundamentals will not take into account other important factors: Jinhe Biotechnology Cash |
|
Jinhe Biotechnology Total Value Analysis
Jinhe Biotechnology Co is presently forecasted to have takeover price of 4.94 B with market capitalization of 3.33 B, debt of 2.3 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Jinhe Biotechnology fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.94 B | 3.33 B | 2.3 B |
Jinhe Biotechnology Investor Information
About 46.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.49. In the past many companies with similar price-to-book ratios have beat the market. Jinhe Biotechnology last dividend was issued on the 31st of May 2024. The entity had 25:10 split on the 17th of May 2016. Based on the key measurements obtained from Jinhe Biotechnology's financial statements, Jinhe Biotechnology Co is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 169.2 M | 228.6 M |
|
| |||||
| Operating Income | 167.7 M | 215.9 M |
|
|
Jinhe Biotechnology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Jinhe Biotechnology has an asset utilization ratio of 39.86 percent. This suggests that the Company is making USD0.4 for each dollar of assets. An increasing asset utilization means that Jinhe Biotechnology Co is more efficient with each dollar of assets it utilizes for everyday operations.Jinhe Biotechnology Ownership Allocation
Jinhe Biotechnology Co has a total of 771.69 Million outstanding shares. Jinhe Biotechnology secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Jinhe Biotechnology Profitability Analysis
The company reported the revenue of 2.17 B. Net Income was 86.46 M with profit before overhead, payroll, taxes, and interest of 665.68 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Jinhe Biotechnology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Jinhe Biotechnology and how it compares across the competition.
About Jinhe Biotechnology Valuation
The stock valuation mechanism determines Jinhe Biotechnology's current worth on a weekly basis. Our valuation model uses a comparative analysis of Jinhe Biotechnology. We calculate exposure to Jinhe Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Jinhe Biotechnology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 738.9 M | 638.3 M |
Jinhe Biotechnology Quarterly Retained Earnings |
|
Complementary Tools for Jinhe Stock analysis
When running Jinhe Biotechnology's price analysis, check to measure Jinhe Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jinhe Biotechnology is operating at the current time. Most of Jinhe Biotechnology's value examination focuses on studying past and present price action to predict the probability of Jinhe Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jinhe Biotechnology's price. Additionally, you may evaluate how the addition of Jinhe Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |